Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2

Different treatment trials have been published in acquired nystagmus in the last decade; gabapentin and memantine have been found to be efficient in treating pendular nystagmus in Multiple Sclerosis. The effects of treatments are measured on nystagmus velocity, amplitude, frequency and on visual acuity. None of the trials measured a functional visual score or oscillopsia score. The aim of our study is to evaluate the effect of gabapentin and memantine on the mean velocity, amplitude and frequency of pendular nystagmus, as well as on oscillopsia, visual acuity and vision-specific health-related quality of life score, in 10 patients with multiple sclerosis. The primary object is to find out the best variable to evaluate the efficiency of nystagmus treatment and the secondary, to compare the efficiency of both gabapentin and memantine in a common population of patients.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria.

• All patients may present a chronic acquired pendular nystagmus due to MS, observed over a period of 6 months.

• All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.

• Age: above 18

• Able to understand the instructions

• Having a health coverage

• Able to sit down for 1 hour

• Stable dosage of previous medications (beginning 3 weeks previously and terminating at the end of the trial duration), except for steroids, gabapentin or memantine.

Other Locations
Hôpital Neurologique Unité de Neuro-Ophtalmologie
Time Frame
Start Date: November 2012
Completion Date: July 2013
Target number of participants: 10
Experimental: Memantine first
Experimental: Gabapentin first
Leads: Hospices Civils de Lyon

This content was sourced from

Similar Clinical Trials